Oppenheimer analyst Andreas Argyrides downgraded Liquidia (LQDA) to Underperform from Perform with a $13 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Liquidia management to meet with Needham
- Liquidia Technologies’ Earnings Call: Legal Wins and Financial Challenges
- Buy Rating for Liquidia Technologies Amid Legal Challenges and Market Potential
- Liquidia Faces Patent Infringement Lawsuit by United Therapeutics
- Liquidia Technologies: Legal Wins and Promising Clinical Data Bolster Buy Rating